Financial Performance - Revenue increased from RMB 53.5 million in 2024 to RMB 95.3 million in 2025, representing a growth of 78.0%[3] - Gross profit rose to RMB 63.98 million in 2025, up 66.6% from RMB 38.41 million in 2024[2] - Net loss decreased significantly from RMB 111.3 million in 2024 to RMB 44.5 million in 2025, a reduction of 60.0%[5] - The company reported revenue from the sale of medical consumables and devices amounting to RMB 95,268,000 in 2025, a significant increase from RMB 53,531,000 in 2024, representing a growth of approximately 77.9%[27] - Other income decreased significantly to RMB 1,125,000 in 2025 from RMB 19,573,000 in 2024, primarily due to a reduction in government grants[31] - The company incurred a pre-tax loss of RMB 44,456,000 in 2025, an improvement from a loss of RMB 111,143,000 in 2024[34] - The company did not declare or pay any dividends during the year, consistent with the previous year[35] - The company reported a basic loss per share attributable to ordinary equity holders of the parent, calculated based on a weighted average of 239,110,000 shares outstanding for the year[36] Research and Development - Research and development expenses decreased from RMB 73.46 million in 2024 to RMB 30.44 million in 2025[6] - The company has established a comprehensive intellectual property portfolio with 180 patents and 40 patent applications as of December 31, 2025[69] - The company plans to accelerate clinical development and commercialization of in-progress products, focusing on minimally invasive cryo-intervention technologies[71] Regulatory Approvals and Product Development - The malignant stenosis cryoablation system received approval from the National Medical Products Administration in March 2025 and was commercialized in May 2025[5] - The asthma cryoablation system was granted breakthrough medical device designation by the U.S. FDA in July 2025[5] - The cardiac cryoablation system received approval from the National Medical Products Administration in December 2023, with commercialization expected in January 2024[48] - The Cryofocus cryoablation system, designed for hypertension treatment, is anticipated to receive approval by the second half of 2027[49] - The pulmonary hypertension cryoablation system is currently in preclinical research, with expected approval by the second half of 2029[50] - The COPD cryo-spray treatment system entered confirmatory clinical trials in March 2023, with registration documents expected to be submitted in the first half of 2027[51] - The asthma cryoablation system is also in confirmatory clinical trials, with registration documents expected to be submitted in the second half of 2027 and approval anticipated in the first half of 2029[52] - The benign stricture cryoablation system is expected to enter confirmatory clinical trials in January 2024, with product registration documents to be submitted to the National Medical Products Administration (NMPA) in the first half of 2027 and anticipated approval in the second half of 2027[54] - The lung nodule cryoablation system is currently in confirmatory clinical trials, with plans to submit registration documents to the NMPA in the second half of 2026 and expected approval in the second half of 2027[55] - The cough cryo-spray treatment system is in feasibility clinical trials, with expected registration submission to the NMPA in the second half of 2027 and anticipated approval in the second half of 2028[56] - The tuberculosis cryo-spray treatment system is also in feasibility clinical trials, with plans to submit registration documents to the NMPA in the second half of 2027 and expected approval in the second half of 2028[57] - The frozen adhesion treatment system received NMPA approval for its supporting cryotherapy equipment in December 2023 and for the disposable cryo-probe in January 2024, with commercialization planned for September 2024[58] - The bladder cryoablation system was approved by the NMPA in June 2022 and was commercialized in China in December 2022[59] - The gastric cryoablation system is currently in feasibility clinical trials, with expected registration submission to the NMPA in the first half of 2027 and anticipated approval in the first half of 2028[60] - The esophageal cryo-spray treatment system is in feasibility clinical trials, with plans to submit registration documents to the NMPA in the first half of 2027 and expected approval in the first half of 2028[61] Financial Position and Assets - Total assets decreased from RMB 98.16 million in 2024 to RMB 91.23 million in 2025[8] - The company's equity total decreased from RMB 78.93 million in 2024 to RMB 48.53 million in 2025[9] - Cash and cash equivalents decreased from RMB 45.46 million in 2024 to RMB 35.03 million in 2025[8] - Trade receivables remained at RMB 74,000, with a corresponding impairment of RMB 74,000, resulting in a net book value of zero[37][39] - Other receivables decreased from RMB 22,828,000 in 2024 to RMB 23,317,000 in 2025, with impairment losses reducing from RMB 901,000 to RMB 571,000[41] - Trade payables increased significantly from RMB 1,205,000 in 2024 to RMB 2,491,000 in 2025, indicating a rise in operational liabilities[42] - Other payables and accrued expenses rose from RMB 21,841,000 in 2024 to RMB 34,879,000 in 2025, reflecting increased operational costs[43] Corporate Governance and Compliance - The company has adopted a code of conduct for securities trading by directors and senior management, confirming compliance throughout the reporting period[101] - The audit committee, consisting of one non-executive director and two independent non-executive directors, has reviewed the financial reporting and internal control systems, ensuring compliance with relevant accounting standards[103] - The company has maintained compliance with the corporate governance code throughout the reporting period and will continue to monitor its governance practices[100] - The company has not purchased, sold, or redeemed any of its listed securities during the reporting period[102] - The company has proposed amendments to its articles of association to abolish the supervisory board, with the changes approved at the extraordinary general meeting[99] Market and Operational Strategy - The company operates primarily in mainland China, with nearly all revenue generated from the sale of medical consumables and devices in that region[24] - The company has a single reportable segment focused on the research and development of medical consumables and devices, with no further segment analysis provided[23] - The company focuses on innovative medical devices in minimally invasive cryotherapy, establishing high entry barriers for competitors[44] - The company aims to expand its market presence in vascular intervention and natural orifice transluminal endoscopic surgery (NOTES) for various diseases[44] Share Issuance and Financing - The company completed the issuance of 5,595,000 H shares in January 2026, raising approximately HKD 29.73 million[5] - The company announced a conditional agreement to issue 7,460,000 H-shares at a subscription price of HKD 5.36 per share, representing approximately 5.20% of the existing issued H-shares and 3.12% of the total issued shares as of the agreement date[106] - The total amount raised from the subscription agreement is approximately HKD 39.99 million, with a net amount of about HKD 39.73 million after expenses, equating to a net issue price of approximately HKD 5.33 per share[107] - The net proceeds from the subscription agreement are intended for research, production, and commercialization of minimally invasive products related to vascular intervention, respiratory intervention, and tumor intervention, with potential overseas business expansion[108] Employee and Operational Metrics - The company employed 174 full-time employees as of December 31, 2025, down from 276 in 2024, with total employee benefits expenses amounting to approximately RMB 74.3 million[96] - The company did not engage in any significant investments, acquisitions, or disposals of subsidiaries, associates, or joint ventures during the reporting period[93] - The company does not have any significant contingent liabilities, guarantees, or litigation threats as of December 31, 2025[92]
康沣生物(06922) - 2025 - 年度业绩